title: Use of defibrotide in the treatment of acute myocardial infarction.
abstract: The results of this preliminary clinical trial confirm the thrombolytic effect of defibrotide demonstrated in preclinical models; demonstrate the positive influence of the product on the natural history of early AMI; suggest that the optimal dosage range should include not less than 1.6 gm of defibrotide during the first hour of treatment; and justify further commitment in the study of defibrotide also beyond the scope of treating AMI.
authors.affiliation: Coronary Care Unit, Echocardiography Service, S. Camillo Hospital, Rome, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Milazzotto
authors.forename: M
authors.initials: M
authors.lastname: Carelli
authors.forename: C
authors.initials: C
authors.lastname: Citone
authors.forename: G
authors.initials: G
authors.lastname: Di Marcotullio
authors.forename: P
authors.initials: P
authors.lastname: Giampaolo
authors.forename: U
authors.initials: U
authors.lastname: Malinconico
authors.forename: C
authors.initials: C
authors.lastname: Polizzi
authors.forename: M
authors.initials: M
authors.lastname: Tubaro
authors.forename: E
authors.initials: E
authors.lastname: Giovannini
authors.forename: L
authors.initials: L
authors.lastname: Boccardi
mesh_terms: D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D015425:Myocardial Reperfusion; D009336:Necrosis; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide